Haleon/$HLN
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Haleon
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Ticker
$HLN
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
24,561
Website
Haleon Metrics
BasicAdvanced
$44B
46.50
$0.21
0.22
$0.18
2.53%
Price and volume
Market cap
$44B
Beta
0.22
52-week high
$11.42
52-week low
$8.86
Average daily volume
13M
Dividend rate
$0.18
Financial strength
Current ratio
0.984
Quick ratio
0.749
Long term debt to equity
53.686
Total debt to equity
63.406
Dividend payout ratio (TTM)
39.53%
Interest coverage (TTM)
6.31%
Profitability
EBITDA (TTM)
3,619.984
Gross margin (TTM)
63.23%
Net profit margin (TTM)
12.84%
Operating margin (TTM)
22.14%
Effective tax rate (TTM)
22.77%
Revenue per employee (TTM)
$620,640
Management effectiveness
Return on assets (TTM)
4.55%
Return on equity (TTM)
8.95%
Valuation
Price to earnings (TTM)
46.5
Price to revenue (TTM)
5.931
Price to book
2.03
Price to tangible book (TTM)
-3.26
Price to free cash flow (TTM)
28.886
Free cash flow yield (TTM)
3.46%
Free cash flow per share (TTM)
34.10%
Dividend yield (TTM)
1.80%
Forward dividend yield
2.53%
Growth
Revenue change (TTM)
-0.61%
Earnings per share change (TTM)
38.94%
3-year revenue growth (CAGR)
5.58%
3-year earnings per share growth (CAGR)
1.41%
What the Analysts think about Haleon
Analyst ratings (Buy, Hold, Sell) for Haleon stock.
Bulls say / Bears say
Haleon forecasts high single-digit percentage growth in profits from 2026, driven by strong demand in key markets and expected supply chain cost reductions. (reuters.com)
The company reported a 3.5% organic revenue growth in Q1 2025, surpassing analysts' expectations of 3.2%, primarily due to increased demand for its oral health products. (reuters.com)
Haleon has allocated £500 million for share buybacks in the current year, indicating confidence in its financial position and commitment to returning value to shareholders. (reuters.com)
GSK reduced its stake in Haleon to approximately 7.4% by selling shares worth around $1.08 billion, potentially signaling a lack of confidence from a major shareholder. (benzinga.com)
Haleon's P/E ratio of 26.87 is higher than the market average of 23.58, suggesting the stock may be overvalued compared to its earnings. (marketbeat.com)
The company reported a 2.3% decline in first-quarter revenue, attributed to a weaker flu season impacting demand for its cold and cough medicines. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Jun 2025.
Haleon Financial Performance
Revenues and expenses
Haleon Earnings Performance
Company profitability
Haleon News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Haleon stock?
Haleon (HLN) has a market cap of $44B as of July 25, 2025.
What is the P/E ratio for Haleon stock?
The price to earnings (P/E) ratio for Haleon (HLN) stock is 46.5 as of July 25, 2025.
Does Haleon stock pay dividends?
Yes, the Haleon (HLN) stock pays dividends to shareholders. As of July 25, 2025, the dividend rate is $0.17731 and the yield is 2.53%. Haleon has a payout ratio of 39.53% on a trailing twelve-month basis.
When is the next Haleon dividend payment date?
The next Haleon (HLN) dividend payment date is unconfirmed.
What is the beta indicator for Haleon?
Haleon (HLN) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.